Video: Accelerating Sterile Injectable Development From Early Clinical Supply to Commercial Readiness, by Dr. John Cameron

In this interview, Dr. John Cameron, Global Commercial Head Injectables – BU Drug Product at CordenPharma, discusses the key challenges innovators face when advancing sterile injectable products from development into clinical and commercial manufacturing. He explains that one of the most common obstacles is the availability of API and the resulting impact on development timelines, particularly in early phases where technical challenges have not yet been fully resolved. He also highlights the importance of having access to a broad range of development capabilities, including formulation development, analytical methods, and flexible fill-finish solutions.

John shares how CordenPharma addresses growing demand for sterile injectable development and manufacturing through targeted investments in both analytical and production capabilities. The company has significantly expanded its analytical development organization, increasing laboratory capacity and resources to support customers more efficiently. CordenPharma is also investing in new isolator fill-finish lines, including a flexible small-scale line designed to support Phase I, Phase II, and small-scale commercial production, as well as a high-speed commercial lines capable of producing approximately 30,000 units per hour.

A key theme throughout the discussion is the value of CordenPharma’s integrated drug substance and drug product offering. By bringing API and sterile injectable development together within a single organization, customers can begin formulation and analytical work earlier, streamline decision-making, and reduce handoffs between suppliers. John explains that this coordinated approach helps compress development timelines, accelerate first-in-human readiness, and improve overall program efficiency.

The interview also highlights how integration can reduce risk for customers. Because CordenPharma manages both API and drug product activities, teams have greater visibility into project timelines and can proactively address potential delays. This enables greater flexibility in scheduling and helps customers avoid disruptions that often occur when multiple vendors are involved. For innovators seeking to move therapies into the clinic as quickly as possible, John emphasizes that the combination of development expertise, flexible capacity, and integrated services can play a significant role in accelerating progress while reducing complexity.